CompletedPhase 2

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

United States202 participantsStarted 2010-04-14

Plain-language summary

The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female patients with symptomatic pulmonary hypertension due to left ventricular systolic dysfunction despite optimized heart failure therapy Exclusion Criteria: * Types of pulmonary hypertension other than group 2.1 of Dana Point Classification

What they're measuring

Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16

Timeframe: Baseline and visit 6 (16 weeks)

Trial details

NCT IDNCT01065454

SponsorBayer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-06-06

Results submitted2013-11-06

View on ClinicalTrials.gov More Hypertension, Pulmonary trials